Skip to content
August 08, 2022

Equity.Guru

Investment information for the new generation

Taylor Gavinchuk

Phase 2 I’ve written previously about how expensive clinical trials are, and how not many companies are actually cashed enough to run the trials they plan on. Companies need…
Common vs preferred shares A company can go bust for a number of reasons. It happens all the time. In those dire circumstances, the retail investors will be the…
Cruel, cruel summer It’s near the end of September and the seasons are changing.   Chet Hanks predicted this past summer would be a ‘white boy summer’. But for…
SPL026 Small Pharma (DMT.V), a psychedelics company focusing on DMT announced today it’s completed Phase 1 for its drug candidate SPL026, (a DMT derivative) for the treatment of Major…
One billion shares No matter what FSD Pharma (HUGE.N) does, I will always remember them as the company that bragged endlessly about having more than a billion shares outstanding….
The MSM Tim Ferriss, author of The 4 Hour Work Week, The 4 Hour Chef, The 4 Hour body etc. is ponying up $800,000 USD in a partnership with…
Keeping up with the Joneses  In 2018 a group of Vancouver lawyers penny stock enthusiasts joined up under The Bridge Mark group to provide unique financing options for weed…
Diverse clinics Ketamine One (MEDI.NE) announced it’s adding 2 more locations to its already bustling ketamine clinic network. Through an acquisition last week, Ketamine One gains control of Illumma…
Mainstream adoption I was 19 rows back, dead center as Roger Waters played Comfortably Numb next to 80-foot Pink Floyd stage props. The MDMA had kicked in long ago,…
Biting the hand that feeds you Nova Mentis Life Sciences (NOVA.C) director Steven Feldman has some interesting thoughts around vaccines, and as a life sciences company, I think it’s…